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Background: Systemic chemotherapy is the key treatment for advanced gastric cancer. The benefit of adjuvant
surgery following preoperative chemotherapy in gastric cancer with liver metastasis has not been well established.
Methods: Forty-nine gastric cancer patients diagnosed with synchronous liver metastasis initially treated with
chemotherapy were categorized into the following two groups: surgery group: 25 patients who underwent
gastrectomy and subsequently received postoperative chemotherapy and control group: 24 patients who received
chemotherapy alone.
Results: The median overall survival of patients in the surgery group and control group was 20.5 and 9.1 months,
respectively, (P = 0.006). The median progression-free survival in the surgery group was 10.9 months, with statistical
significance when compared with 5.0 months in the control group (P = 0.001). Multivariate analysis demonstrated
that response to chemotherapy was the only independent factor in predicting prognosis. The survival of patients
who achieved partial response (PR) was prolonged if they received adjuvant surgery (P = 0.024). No significant
difference in the survival of patients underwent combined hepatic resection when compared with patients
performed gastrectomy only.
Conclusions: For gastric cancer with synchronous liver metastasis, adjuvant gastrectomy followed by
chemotherapy might be beneficial for survival comparing with chemotherapy alone, especially in patients response
to initial preoperative chemotherapy.
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Gastric cancer is one of the most common malignancies in
the world. In China, it is the second leading cancer cause
of death ranking after lung cancer [1]. It is commonly de-
tected at advanced stages for its initial stage often lack of
specific symptom. Liver metastasis is one of the prognostic
factors predicting poor survival in gastric cancer. Nearly
5–10 % of gastric cancer patients have involvement of syn-
chronous liver metastasis when get diagnosis [2].* Correspondence: jiafujpku@163.com
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creativecommons.org/publicdomain/zero/1.0/Systemic chemotherapy is the key treatment for advanced
gastric cancer (AGC). Multiple trails of various chemother-
apeutic regimens have been conducted to prolong the
survival of patients with AGC. Classical chemotherapy regi-
mens for AGC include CF and ECF [3]. Paclitaxel is an
anti-mitotic drug which had been widely used in the treat-
ment of a variety of tumors including gastric cancer. Clin-
ical trials have confirmed the safety and efficiency of
paclitaxel and capecitabine (PX) combination chemother-
apy in AGC [4–6].
Although great progress has been achieved in chemo-
therapy, the outcome of patients with AGC is still poor.
Tumor progression is common in patients with tempor-
ary regression after chemotherapy due to drug resist-
ance. Surgery is another way to get a long-time survivaldistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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surgery for AGC, especially for the liver metastasis from
gastric cancer, is still elusive [7–14]. Recently, Suzuki
et al. reported that adjuvant surgery was effective follow-
ing the response of chemotherapy in AGC patients with
liver metastasis [15]. In some cases, the adjuvant surgery
resulted in further long-term survival. Nevertheless,
solid evidence from prospective study is lacking.
This study therefore aimed to investigate whether adju-
vant surgery followed by chemotherapy was more benefi-
cial than chemotherapy alone in gastric cancer patients
with synchronous liver metastasis following preoperative
chemotherapy.
Methods
Patients and study scheme
This study included 49 patients with AGC treated be-
tween June 2008 and December 2011 in Beijing Cancer
Hospital. All patients were diagnosed with synchronous
liver metastases and placed on a chemotherapy regimen,
paclitaxel plus capecitabine (PX). Then, patients were di-
vided into two groups based on their preference after
multidisciplinary team (MDT) discussion. The surgery
group underwent adjuvant gastrectomy (D2) followed by
postoperative chemotherapy (PX). The control group re-
ceived the same chemotherapy as described above with-
out any operation (Additional file 1). Informed written
consent was obtained from all patients, and the study
was approved by the ethical committee in Beijing Cancer
Hospital, China.
Inclusion criteria
Patients were histologically proven gastric adenocarcinoma
with hepatic metastasis identified by CT/MRI (AJCC TNM
Version 7). No peritoneal or other distant metastasis; age
range, ≥18 years; Karnofsky score ≥70; D2 lymph node dis-
section at palliative gastrectomy (no. of lymph node ≥15);
no concurrent diseases that can cause death in 3 months;
adequate major organ function (hemoglobin ≥90 g/L; neu-
trophil count ≥1.5 × 109/L; platelet count ≥100 × 109/L;
ALB ≥30 g/L; AST, ALT, and ALP ≤2.5 times the upper
limit of normal; total bilirubin <1.5 times the upper limit of
normal; creatinine lower than the upper limit of normal).
Chemotherapy regimen
Capecitabine (1000 mg/m2) was administered orally within
30 min after morning and evening meals for 2 weeks,
followed by a drug-free interval of 1 week (one cycle). Pac-
litaxel (80 mg/m2) was diluted in 0.9 % saline and adminis-
tered as a 2-h infusion in the morning of day 1 and day 8
of each cycle (i.e., every 3 weeks). The paclitaxel infusion
was started simultaneously with the capecitabine adminis-
tration. Responses were classified according to the RECIST
guidelines. Patients in the surgery group were placed onpostoperative chemotherapy within 4 to 6 weeks after
gastrectomy.
Definition of adjuvant gastrectomy
Patients with progressive disease are considered not suit-
able for resection. Adjuvant gastric resection included the
absence of primary tumor, both macroscopically and micro-
scopically, by D2 lymphadenectomy. Resection margin was
not less than 5 cm for partial gastrectomy. In total gastrec-
tomy, proximal resection margin was not less than 2 cm
while distal resection margin was not less than 5 cm.
Simultaneous hepatic resection was conducted when
the liver metastasis could be curative resected through
the evaluation.
Follow-up
Patients were assessed every month to detect any adverse
events with verbal interview, physical examination, and
blood tests, including a complete blood cell count and
measurements of liver and renal function, until disease
progression. Abdominal CT/MRI and measurements of
CEA and CA19-9 were carried out every 3 months. Over-
all survival was defined as the time from diagnosis of
AGC with synchronous liver metastases to death from
any cause or last follow-up. Progression-free survival
(PFS) was defined as the length of time after treatment
during which the disease did not get worse.
Statistical analysis
Data related to patient characteristics were compared be-
tween the two groups by using the chi-square test. Data
on patients who were alive or lost to follow-up were cen-
sored. The primary end point was survival. Cumulative
survival was estimated with the Kaplan-Meier method
(SPSS version 19 software), and comparisons between the
groups were done with a log-rank test. A multivariate ana-
lysis of the Cox proportional hazards regression model
(backward, stepwise) was created to assess the influence of
each variable on survival. Significance was set at P < 0.05.
Results
Patient characteristics
A total of 49 AGC patients with synchronous liver metas-
tases were treated in this study. Table 1 shows the patient
characteristics. There were no major imbalances between
the two groups in terms of characteristics of primary gas-
tric cancer except with regard to the primary tumor loca-
tion. In the surgery group, 25 % of the primary tumor
occurred at EGJ or upper third of stomach, signifi-
cantly lower than 42.9 % of which in the control group
(P = 0.003). No statistical significance was identified in
age, Borrmann type, histological grade, pathological classi-
fication, and T stage between the two groups (P > 0.05).










Age 61.4 ± 9.5 60.8 ± 7.9 0.834







EGJ 4 (16.7 %) 0 (0 %)
U 2 (8.3 %) 9 (42.9 %)
M 3 (12.5 %) 5 (23.8 %)
L 15 (62.5 %) 7 (33.3 %)
Borrmann type 0.355
I 0 (0 %) 0 (0 %)
II 3 (13.6 %) 4 (21.1 %)
III 19 (86.4 %) 14 (73.7 %)




9 (40.9 %) 9 (45.0 %)
Median and low
differentiation
0 (0 %) 1 (5.0 %)
Median
differentiation
4 (18.2 %) 4 (20.0 %)
High and median
differentiation




Adenocarcinoma 22 (91.7 %) 21 (100 %)
Small cell carcinoma 1 (4.2 %) 0 (0 %)
Signet ring cell
carcinoma




T2 3 (13.0 %) 1 (5.0 %)
T3 1 (4.3 %) 0 (0 %)
T4a 17 (73.9 %) 15 (75.0 %)
T4b 2 (8.7 %) 4 (20.0 %)
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All 49 patients were placed on three courses of chemother-
apy (PX). Response evaluation of patients after chemother-
apy was shown in Additional file 2. In the surgery group,
14 (60.9 %) patients achieved partial response (PR) and 8
(34.8 %) patients reached stable disease (SD), significantly
higher when compared with 7 (31.8 %) PR and 3 (13.6 %)
SD in the control group (P = 0.001). All patients were
assessed for toxicities that are listed in Additional file 3. Pa-
tients were generally well tolerated throughout the study.Adverse events associated with PX were observed in 31
(63.3 %) patients. The most common adverse effects were
fatigue (44.9 %) and anemia (36.7 %). Grade 4 adverse
events were rare. Dose reduction in chemotherapy oc-
curred in five (12.2 %) patients.
A total of 25 patients underwent adjuvant gastrectomy
followed by postoperative chemotherapy. As shown in
Additional file 4, eight (32.0 %) patients received total
gastrectomy. Thirteen (52 %) patients underwent com-
bined hepatic resection with gastrectomy. Postoperative
complications included gastroparesis and abdominal in-
fections occurred in four (16 %) patients.Patient survival
Median lengths of follow-up in the surgery group and con-
trol group were 19.6 and 9.5 months, respectively. The me-
dian overall survival (OS) of patients in the surgery group
was 20.5 months, which was statistically more prolonged
than 9.1 months in the control group (Fig. 1a, P = 0.006).
The 1- and 2-year survival rates were 72 and 32 % in the
surgery group and 41 and 8 % in the control group, respect-
ively. In addition, the median PFS in the surgery group was
13.0 months, with statistical significance when compared
with 5.8 months in the control group (Fig. 1b, P = 0.005).
We next analyzed the survival efficacy of chemotherapy
in all AGC patients. Patients were divided into three groups
based on the response to PX. The median OS of patients
who achieved PR was 23.3 months, significantly longer than
18.7 and 6.1 months in patients who achieved SD and pro-
gression disease (PD), respectively (Fig. 1c, P < 0.001). In
this study, more patients who achieved PR and SD were en-
rolled in the surgery group than in the control group after
MDT discussion. Subsequently, we performed the sub-
group analysis according to the response to chemotherapy.
The median OS in patients who achieved PR after chemo-
therapy in the surgery and control groups was 30.0 and
10.2 months, respectively, with significant statistical differ-
ence (Fig. 1d, P = 0.024). No significant difference of OS
was identified in patients who reached SD after chemother-
apy (data not shown).
To illustrate the efficacy of the hepatic resection in
AGC with liver metastasis, we compared the survival of
patients in the surgery group who underwent combined
hepatic resection or not. The median OS was 16.3 months
in patients with combined hepatic resection, with no stat-
istical significance when compared with 30.0 months in
patients without hepatic resection (Fig. 2a, P = 0.235). Im-
portantly, among the patients who have achieved PR after
preoperative chemotherapy, the median OS in patients
who underwent combined gastric and hepatic resection
was 23.3 months, with no statistical significance when
compared with 30.0 months in patients treated with gas-
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Fig. 1 Kaplan-Meier curves for survival in AGC patients with liver metastasis. a, b Comparison of OS and PFS between the adjuvant surgery and
chemotherapy group. c Comparison of OS among the various responses to chemotherapy (PR, SD, and PD). d Comparison of OS between patients who
initially achieved PR after chemotherapy then underwent adjuvant surgery and patients who only treated with chemotherapy initially achieved PR
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patients developed imaging-defined progression. Then, we
classified the patients into two groups: one underwent
anti-tumor treatment after progression and the other re-
ceived supportive care after progression. The median OS
was 16.3 months in the group underwent anti-tumor
treatment, with statistical significance when compared
with 5.6 months in the group received supportive care
after progression (Fig. 3a, P = 0.001). Among the 43 pa-
tients, 16 patients have reached PR after initial chemother-
apy. Eleven of the 16 patients underwent adjuvant
gastrectomy, while the remaining patients were only
treated with chemotherapy. The median OS of the 11patients was 30.0 months, significantly prolonged than 9.9
months in the remaining ones (Fig. 3b, P = 0.021).
Univariate and multivariate analyses of prognosis factors
The results of the univariate analysis are shown in
Additional file 5. The following two factors were found
to be univariately related to better outcomes: response
to chemotherapy (P < 0.001) and adjuvant gastrectomy
(P = 0.006). No survival difference was found in age, gen-
der, primary tumor location, Bormann type, pathological
classification, and T stage (P > 0.05). Multivariate analysis
demonstrated response to chemotherapy as an independ-
ent factor in predicting prognosis (Table 2, P = 0.026).
Patients underwent 
gastrectomy




Patients underwent gastric 
and hepatic resection
P =0.235 P =0.338
A B
Fig. 2 Kaplan-Meier curves for survival in patients who underwent adjuvant surgery. a Comparison of OS between patients who underwent
gastrectomy and patients treated with combined gastric and hepatic resection. b Comparison of OS between patients who initially achieved PR
after chemotherapy then underwent gastrectomy and patients who initially achieved PR after chemotherapy then treated with combined gastric
and hepatic resection
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Gastric cancer is the leading cause of cancer-related death
in the world. Outcome for patients with AGC is extremely
poor. The treatment strategy for AGC with synchronous
liver metastasis is still not well established. Combined
chemotherapy is a way to improve survival and quality of






Fig. 3 Kaplan-Meier curves for survival in patients with tumor progression.
supportive care after tumor progression. b Comparison of OS between the
tumor progression who initially reached PR after chemotherapyII study of PX to evaluate this combination in AGC [6].
Results were promising which included high response rate
(44.5 % PRs) and prolonged patient survival (median OS:
11.3 months). In our current, single-center trial of AGC
with synchronous liver metastasis, consistent with previ-
ous studies, pretreatment with PX resulted in an overall





a Comparison of OS between patients with anti-tumor treatment and
adjuvant surgery and chemotherapy group among patients with
Table 2 Multivariate analysis of prognostic factors for OS of
AGC patients with synchronous liver metastasis
Variables HR CI (95 %) P value
Underwent gastrectomy 1.327 0.501–3.517 0.569
Response evaluation 0.026
SD vs. PR 0.228 0.076–0.682 0.008
PD vs. PR 0.292 0.096–0.888 0.030
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is indicated to provide palliation of the active symptoms
such as bleeding and obstruction; nevertheless, the role
of gastric resection in the treatment of patients with
minimal symptoms and non-curative factors including
liver metastasis remains controversial. Studies have re-
ported improved survival in AGC patients who underwent
palliative gastrectomy when compared to those who had
not [9, 10, 12]. Lin et al. reported that both survival time
and palliative duration were significantly longer in patients
with stage IV gastric cancer after palliative gastrectomy
than non-resection operations [12]; however, others im-
plied that no patients or only a selected subsets of patients
with AGC might benefit from non-curative gastrectomy
[8, 11]. Li et al. demonstrated that only patients with sin-
gle peritoneal dissemination had survival benefit from pal-
liative resection while others with single liver, distant
lymph nodes, or multiple sites metastasis had none [11].
One possible reason for the persistent controversy is that
heterogeneous patients with different clinical parameters
were enrolled in different studies. For example, multior-
gan metastasis could be a factor for predicting poor prog-
nosis of AGC.
Recently, increasing studies have evaluated the combined
efficacy of non-curative surgery with peri-operative sys-
temic chemotherapy in AGCs. The preoperative chemo-
therapy aimed to downstage the primary tumor while
postoperative chemotherapy was administered to treat the
residual cancer and micrometastasis. Kokkola et al. re-
ported that patients with metastatic gastric cancer under-
went gastrectomy followed by postoperative chemotherapy
had better median OS than patients who underwent gas-
trectomy without chemotherapy [16]. In another study, the
median OS of AGC patients underwent gastrectomies after
the response to chemotherapy reached 28.5 months [15],
which was more prolonged than the range for median sur-
vival (5~24 months) in patients who underwent non-
curative gastrectomy [17]. Patients might benefit from the
non-curative surgery when preoperative chemotherapy was
effective. However, most of these studies were retrospective
studies with limited number of patients enrolled, and
prospective trials are warranted to determine the value
of adjuvant gastrectomy following preoperative chemo-
therapy in AGCs.In this study, we prospectively compared the efficacy of
adjuvant surgery plus chemotherapy (PX) with chemo-
therapy alone following the response to neoadjuvant/pre-
operative chemotherapy for AGC with synchronous liver
metastasis. Both median OS and PFS of patients in the
surgery group were statistically more prolonged than
chemotherapy-only group. However, in the multivariate
analysis, response to chemotherapy was the only positive
prognostic factor in AGCs, with no effect on the adjuvant
surgery. In this trial, more patients who achieved PR and
SD were enrolled in the surgery group than in the control
group for a curative intention. Poor survival in the control
group might be caused by high PD rate in this group.
In the subgroup analyses, the survival of patients who
achieved PR was prolonged if they received adjuvant
surgery. For this reason, a subgroup of patient could
benefit from adjuvant surgery following the response to
chemotherapy.
Another important issue is about the surgical resection
of hepatic metastasis from AGC. Liver metastases from
gastric cancer are rarely recommended to surgery for they
are often complicated with other distant metastasis. A
number of studies have reported that the efficacy of hep-
atic resection for liver metastases from gastric cancer was
doubtful, while others showed that the combined hepatic
resection leads to long-term survival in some selected pa-
tients [7, 13, 14]. Even though, indications for surgery
could be considered relay on the analysis of prognostic
factors for gastric cancer with liver metastasis. Patients
with good prognostic capacity might benefit from hepatic
resection. Kodera et al. concluded that both “number of
metastatic nodules” and “solitary tumor” were common
independent prognostic factors for the gastric cancer with
hepatic metastasis [18]. Others indicated that patients
with synchronous solitary liver metastasis and without
serosal invasion could be the criteria for liver resection
[19, 20]. To enrich the evidence for combined hepatic re-
section in AGC with liver metastasis, we compared the
survival of patients who underwent liver surgery or not.
Results showed that patients who underwent gastrectomy
plus hepatic resection suffered poor outcomes. No clinical
benefit of hepatic resection was found when AGC patients
with liver metastasis were treated. The possible reason is
that most of the patients enrolled in our study were diag-
nosed with multiple metastasis nodules. Systemic therapy
is still the main strategy for patients with multiple metas-
tasis lesions.
In addition, treatment failure is common in AGC patients
with liver metastasis. The optimal treatment strategy after
treatment failure remains a clinical concern. In our study,
most of the patients who have failed the initial treatment
accepted a secondary anti-tumor therapy including sys-
temic chemotherapy, radiotherapy, or interventional treat-
ment. The remaining four patients who received supportive
Li et al. World Journal of Surgical Oncology  (2015) 13:212 Page 7 of 7care all died in 10 months. The anti-tumor treatment
prolonged the survival to 16.3 months. Thus, patients
who failed the initial treatment would benefit from sec-
ondary anti-tumor therapy. Interestingly, among pa-
tients with treatment failure, 16 of them reached PR
after chemotherapy. Eleven of the 16 patients who
underwent gastrectomy had better outcome than the
rest who did not treat with surgery. Accordingly, pa-
tients with tumor progression following a temporary
regression to chemotherapy could also benefit from the
adjuvant surgery after the initial chemotherapy.
Conclusions
PX is a promising combined chemotherapy regimen for
AGC with liver metastasis. Response to chemotherapy is
the only independent prognostic factor for patient sur-
vival. Adjuvant gastrectomy is reasonable in patients re-
sponse to preoperative chemotherapy. More evidence is
needed for the resection of liver metastasis from AGC.
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Additional file 1: The study scheme. Patients were enrolled into two
groups based on their preference after MDT discussion.
Additional file 2: Response evaluation of all AGC patients with
synchronous liver metastasis after three courses of chemotherapy
(PX). More patients in the surgery group achieved PR and SD after
chemotherapy than in control group.
Additional file 3: Adverse events of chemotherapy in all 49
patients. Patients were generally well tolerated in this study.
Additional file 4: Summary of 25 AGC patients underwent adjuvant
gastrectomy. About half patients underwent combined hepatic
resection with gastrectomy.
Additional file 5: Univariate analysis of prognostic factors for OS of
AGC patients with synchronous liver metastasis. Response to
chemotherapy and adjuvant gastrectomy were factors related to better
outcomes.
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